Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

NCT00010049 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

105

Enrollment

OTHER

Sponsor class

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG: imatinib mesylate

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]